Infusystem Holdings, INC 8-K filings

InfuSystem Holdings, Inc. will release its preliminary financial results for the fourth quarter and full year 2024 on March 4, 2025, followed by an investor conference call.

InfuSystem Holdings highlights five consecutive years of record revenue, a strong balance sheet, and strategic growth initiatives in a new investor presentation.

InfuSystem Holdings, Inc. will present at the Sidoti Small Cap Virtual Investor Conference on December 4, 2024, with a webcast available on the company's website.

InfuSystem Holdings has appointed Ronald Hundzinski, a seasoned financial executive, to its Board of Directors, effective November 12, 2024.

InfuSystem Holdings announced record net revenues of $35.3 million for the third quarter of 2024, representing an 11% increase year-over-year, alongside a significant rise in net income and adjusted EBITDA.

InfuSystem Holdings, Inc. will release its third quarter 2024 financial results on November 7, 2024, before the market opens, followed by an investor conference call.

InfuSystem Holdings, Inc. announced that its CEO, President/COO, and CFO will participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024.

InfuSystem Holdings, Inc. released an investor presentation on September 12, 2024, showcasing its growth, strategic partnerships, and financial performance.

InfuSystem and Sanara MedTech have entered an exclusive distribution agreement with ChemoMouthpiece, LLC for its oral cryotherapy device in the United States.

InfuSystem Holdings, Inc. announces that its CEO and CFO will participate in the Lake Street Capital Markets' 8th Annual Best Ideas Growth Conference on September 12, 2024.

InfuSystem Holdings, Inc. reported record net revenues of $33.7 million for the second quarter of 2024, representing a 6% increase year-over-year, and reaffirmed its full-year 2024 guidance.

InfuSystem Holdings, Inc. has announced a three-year distribution agreement with Smith+Nephew for its RENASYS EDGE negative pressure wound therapy system.

InfuSystem Holdings, Inc. will release its second quarter 2024 financial results before market open on August 8, 2024, followed by an investor conference call.

InfuSystem Holdings presented its investor presentation on June 12, 2024, showcasing its growth strategy, financial performance, and competitive advantages.

InfuSystem Holdings, Inc. will present at the Sidoti Small Cap Virtual Investor Conference on June 12, 2024, with a webcast available on the company's website.

InfuSystem Holdings, Inc. has announced a new $20 million stock repurchase program, superseding a previous authorization, demonstrating confidence in the company's operations and financial position.

InfuSystem Holdings held its 2024 Annual Meeting of Stockholders on May 16, 2024, where all board nominees were elected, executive compensation was approved on an advisory basis, and Deloitte & Touche LLP was ratified as the independent accounting firm.

InfuSystem Holdings, Inc. announced a 5% increase in net revenues to $32.0 million for the first quarter of 2024, driven by strong growth in its Device Solutions segment and an improved gross margin.

InfuSystem Holdings, Inc. will release its first quarter 2024 financial results before the market opens on May 9, 2024, followed by an investor conference call.

InfuSystem Holdings has received a notice from the NYSE American for failing to file its annual report on time, potentially leading to delisting.

InfuSystem Holdings announced record net revenues of $125.8 million for 2023, a 14% increase year-over-year, driven by growth in both Patient Services and Device Solutions.

InfuSystem Holdings, Inc. has announced the resignation of director R. Rimmy Malhotra, effective March 8, 2024, as part of a cooperation agreement with Nicoya Capital LLC.

InfuSystem Holdings, Inc. will release its preliminary fourth quarter and full year 2023 financial results on March 14, 2024, before the market opens, followed by an investor conference call.